Immune Checkpoint Inhibitor Market

Immune Checkpoint Inhibitor Market Synopsis

The Global Immune Checkpoint Inhibitor Market was valued at USD 191.9 billion in 2023 and is expected to grow from USD 203.0 billion in 2024 to USD 337.3 billion by 2033, reflecting a CAGR of 5.8% over the forecast period.

The market for immune checkpoint inhibitors is expanding rapidly due to more people getting cancer and improved treatments in immunotherapy. As a result of using immune checkpoint inhibitors, the PD-1, PD-L1, and CTLA-4 proteins are blocked by the immune system, which previously allowed cancer cells to escape. Stopping the pathways with drugs makes the immune system better able to detect and destroy cancer cells. Experts are noticing that the market is expanding because of more new drugs being used, an increase in combination therapies, and large investments in research. Merck & Co., Bristol-Myers Squibb, and Roche are among the top pharmaceutical firms, and they offer successful drugs such as Keytruda, Opdivo, and Tecentriq.

Immune Checkpoint Inhibitor Market Driver Analysis

Expanding Use in Combination Therapies

Treatment options for cancer are advancing a lot because of the successful use of checkpoint inhibitors in different combinations. While checkpoint inhibitors have proven to be very useful in certain types of cancer, when they are used with other therapies, patients benefit from better anti-tumor activities, better ways to fight drug resistance, and longer survival. Release of more tumor antigens from chemotherapy helps the immune system detect cancer cells and gain benefits from using checkpoint inhibitors. Likewise, using targeted therapy disrupts how cancer cells grow and encourages a stronger effect when given together with immunotherapy.

Immune Checkpoint Inhibitor Market Restraint Analysis

Immune-Related Adverse Effects

Immune checkpoint inhibitors can enhance the body’s cancer-fighting abilities, but many patients experience severe immune-related reactions that make it difficult and dangerous to keep them in treatment. As a result of blocking immune checkpoints such as PD-1, PD-L1, or CTLA-4, treatments can trigger the immune system to target both cancer cells and healthy tissue always. As a result, patients can experience unwanted problems such as colitis, pneumonitis, hepatitis, problems with their endocrine system, and skin problems. Serious cases of these immune side effects may mean suspension of the treatment, admission to a hospital, or using corticosteroids.

Immune Checkpoint Inhibitor Market Opportunity Analysis

Expansion into New Indications

Researchers are carrying out trials to test the efficacy of checkpoint inhibitors not only in main cancers but also in various uncommon and non-cancer conditions. They have been quite successful for melanoma, lung cancer, and bladder cancer, so now scientists are investigating if they have the same benefit for malignancies such as mesothelioma, sarcomas, and some brain cancers, whose treatments tend to be more limited. Furthermore, experts are investigating the use of checkpoint inhibitors in diseases not caused by cancer, for instance, persistent infections, autoimmune diseases, and even Alzheimer’s disease. The trials hope to activate the patient’s immune system to achieve balance or to get rid of harmful cells.

Immune Checkpoint Inhibitor Market Trend Analysis

Shift Toward Combination Therapies

Experts see that it is now typical for checkpoint inhibitors to be used with other medicines to boost their result and overcome treatment resistance. Though checkpoint inhibitors have made a big difference in cancer care, they do not always work for certain people because of resistance. Therefore, more professionals are now turning to using chemotherapy, distinctive treatments, radiation, and different immunotherapy methods together. The use of chemotherapy and radiation can together cause tumors to become more susceptible to immune action, while taking targeted therapies can stop cancer cells from avoiding the immune system.

Immune Checkpoint Inhibitor Market Segment Analysis:

The Immune Checkpoint Inhibitor Market is segmented on the basis of Type, Application, and Distribution Channel.

By Type

o   PD-1

o   CTLA-4

o   PD-L1

o   Other Types

By Application

o   Breast Cancer

o   Lung Cancer

o   Colorectal Cancer

o   Bladder Cancer

o   Cervical Cancer

o   Melanoma

o   Hodgkin Lymphoma

o   Other Applications

By Distribution Channel

o   Hospital Pharmacy

o   Retail Pharmacy

o   Online Pharmacy

By Region

o   North America (U.S., Canada, Mexico)

o   Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

o   Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

o   Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)

o   Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

o   South America (Brazil, Argentina, Rest of SA)

By Type, PD-1 Segment is Expected to Dominate the Market During the Forecast Period

Of the types discussed in this research study, the PD-1 segment is expected to account for the largest market share of immune checkpoint inhibitor market in the forecast period. PD-1 inhibitors, for example Keytruda (pembrolizumab) and Opdivo (nivolumab), work well in treating non-small cell lung cancer (NSCLC), melanoma, kidney cancer, and head and neck cancers. This action of PD-1 inhibitors is to block the PD-1 receptor on T cells, leading to an increase in the T cells’ response to tumor cells. Because of effective medical treatments, many new approvals, and venturing into different areas, this segment is still expanding steadily.

By Application, the Lung Cancer Segment is Expected to Held the Largest Share

The lung cancer segment is expected to hold the largest share of the immune checkpoint inhibitor market during the forecast period, primarily due to the high global prevalence of the disease and the strong clinical effectiveness of checkpoint inhibitors in its treatment. In particular, NSCLC was greatly helped by PD-1 and PD-L1 inhibitors such as Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Opdivo (nivolumab). Most patients with this characteristic receive these treatments, either by themselves or together with chemotherapy.

By Distribution Channel, the Hospital Pharmacy Segment is Expected to Held the Largest Share

The hospital pharmacy segment is expected to hold the largest share of the immune checkpoint inhibitor market during the forecast period, owing to the specialized nature and high cost of these therapies, which typically require administration in a clinical setting. The majority of immune checkpoint inhibitors are given to patients intravenously, and this requires close monitoring for potential side effects because of the skills needed to benefit from them—things that hospitals have in place. In addition, when treating advanced or spread-out cancers with immunotherapy, hospitals are generally the main centers for cancer care. Since oncology, infusion centers, and patient management systems exist, hospital pharmacies are even better suited to distribute these drugs.

Immune Checkpoint Inhibitor Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period 

North America is projected to dominate the immune checkpoint inhibitor market throughout the forecast period, driven by several key factors. Due to strong healthcare facilities, significant healthcare investment, and quick adoption of new cancer treatments, the region is well-served. Because there are significant pharmaceutical companies, a lot of research and development, and many active clinical trials, the field is able to bring out new products fast. The involvement of the FDA and other reliable agencies encourages the speed of bringing new drugs to the market. There are many cases of cancer in North America, while people are also more aware and have easy access to immunotherapy, which helps the market expand. Additionally, having favorable insurance for treatment and strong connections between oncology centers improves the region’s access to immune checkpoint inhibitors, putting it in charge of the market.

Recent Development

·       In September 2023, Merck & Co.'s supplemental new drug application for WELIREG (belzutifan), intended for previously treated patients with renal cell carcinoma, has been accepted for priority review by the U.S. FDA.

·       In October 2023, Bristol Myers Squibb received U.S. FDA approval for Opdivo (nivolumab) to treat completely resected stage IIB or stage IIC melanoma in adults and pediatric patients aged 12 years and older.

Active Key Players in the Immune Checkpoint Inhibitor Market

o   F. Hoffmann-La Roche Ltd.

o   Sanofi

o   Bristol-Myers Squibb Company

o   Merck & Co.

o   Eli Lilly and Company

o   GlaxoSmithKline PLC

o   AstraZeneca PLC

o   Regeneron Pharmaceuticals Inc.

o   Shanghai Jhunsi Biosciences Ltd

o   Immutep Ltd

o   BeiGene Ltd

o   Other Key Players

Global Immune Checkpoint Inhibitor Market Scope: